1. Scrip

BioNTech: We Could Produce New COVID Variant Vaccine In Six Weeks, If Needed

Confident That Existing Vaccine Still Works

 
• By Andrew McConaghie

The speed of the new messenger RNA platforms could once again come to the rescue, but fortunately the existing vaccines should remain effective against the emerging strain.

London lockdown
London and the South East of England are now in 'Tier 4' lockdown, thanks largely to the new fast-spreading strain of SARS-CoV2

News that a new variant of COVID-19 is spreading rapidly in the UK has caused alarm around the world, but scientists are generally confident that newly authorized vaccines and antibody treatments will still be effective against the emerging strain.

Eli Lilly believes its antibody treatment will still work against the new variant, while BioNTech is also confident...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.